Mersana Therapeutics, Inc., a biopharmaceutical company developing its FleximerA antibody-drug conjugate platform and pipeline of small molecule Fleximer conjugates, announced today that new data related to its conjugation technology used to create next-generation ADCs is being presented in a poster session at the 2013 Annual Meeting of the ... (more)
http://www.businesswire.com/news/topix/20130409006060/en
http://www.businesswire.com/news/topix/20130409006060/en
No comments:
Post a Comment